Clinical Trials Directory

Trials / Unknown

UnknownNCT04180501

SRS Sequential Sindilimab in Brain Metastasis of NSLSC

A Phase II Study on the Treatment of Advanced Non-small Cell Lung Cancer With Brain Metastasis by SRS Sequential Sintilimab

Status
Unknown
Phase
Phase 2
Study type
Interventional
Enrollment
25 (estimated)
Sponsor
Xiaorong Dong · Academic / Other
Sex
All
Age
18 Years – 70 Years
Healthy volunteers
Not accepted

Summary

A phase II study on the treatment of advanced non-small cell lung cancer with brain metastasis by SRS sequential sintilimab

Conditions

Interventions

TypeNameDescription
COMBINATION_PRODUCTSRS sequential sintilimabThe subjects first received a targeted radiotherapy of SRS, and started the treatment of sintilimab per 3 weeks within 35 days after SRS.

Timeline

Start date
2019-11-01
Primary completion
2021-09-01
Completion
2021-12-01
First posted
2019-11-27
Last updated
2019-11-27

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT04180501. Inclusion in this directory is not an endorsement.

SRS Sequential Sindilimab in Brain Metastasis of NSLSC (NCT04180501) · Clinical Trials Directory